NCT06299436Recruiting
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
Source: ClinicalTrials.gov · Last updated 12 Jan 2026
Brief summary (registry, in English)
Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 1 Mar 2024
- Start date
- 10 Dec 2024
- Primary completion date
- 31 Mar 2029
- Lead sponsor
- Johns Hopkins University
- NCT number
- NCT06299436
What you commit to
- Study type: Observational
- Planned participants: 50
- From 10 Dec 2024 to the primary completion date, 31 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Acute hospitalization or decompensation within 2 weeks prior to study date
- Participation in a study involving an investigational drug within 4 weeks prior to study date
Lab values
- Point of care International Normalized Ratio (INR) \> 1.5
Other
- Unable to interrupt VKA anticoagulation
- Pregnant patients
- Inability to lie flat in the supine position
- Symptomatic hemodynamic instability at rest or during the procedure
Who the study is looking for
- Adult patients aged between 18 and 90 years of age
- Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%)
- Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins Hospital Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.